Introduction The treatment of neurological diseases is significantly hampered by the lack of
available therapeutics. A major restraint for the development of drugs is denoted by the …

An exciting development in the field of neurodegeneration is the association between the
rare monogenic disorder Gaucher disease and the common complex disorder Parkinson …

Fluorogenic substrates are emerging tools that enable studying enzymatic processes within
their native cellular environments. However, fluorogenic substrates that function within live …

There is increasing evidence for blood–brain barrier (BBB) alterations in Parkinson's
disease (PD), the second most common neurodegenerative disorder with rapidly rising …

Background: Mutations in GBA1, which encodes the lysosome enzyme ß-
glucocerebrosidase (also referred to as acid ßglucosidase or GCase), are the most common …

Idiopathic Parkinson's disease (PD) is characterized by the loss of dopaminergic neurons in
the substantia nigra pars compacta, which is associated with neuroinflammation and …

Existing strategies use bifunctional chimaeras to mediate extracellular protein degradation.
However, these strategies rely on specific lysosome-trafficking receptors to facilitate …

Alzheimer's and Parkinson's diseases are two of the most frequent neurological diseases.
The clinical features of AD are memory decline and cognitive dysfunction, while PD mainly …

Glucocerebrosidase (GCase) is implicated in both a rare, monogenic disorder (Gaucher
disease, GD) and a common, multifactorial condition (Parkinson's disease, PD); hence, it is …

Background The blood brain barrier limits entry of macromolecular diagnostic and
therapeutic cargos. Blood brain barrier transcytosis via receptor mediated transport systems …